Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Gavin Choy"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7ba191b79015405586e091fa438ea482
Autor:
Kenneth P. Nephew, John J. Turchi, Daniela Matei, John Lyons, Michael Wagner, Pamela VanderVere-Carozza, Katherine S. Pawelczak, Mohammad Azab, Gavin Choy, Jay Pilrose, David F.B. Miller, Yinu Wang, Pietro Taverna, Jessica Tang, Joanne Munck, Fang Fang
Supplementary methods Supplementary Tables S1-S6 Supplementary Figure legends for SF1-SF11 Supplementary Table S1. Primers used for qRT-PCR Supplementary Table S2. Primers used for pyrosequencing Supplementary Table S3. IC50 values for CDDP resensiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006e49c1e43e49a4222238ad9f2b16f7
https://doi.org/10.1158/1078-0432.22459250
https://doi.org/10.1158/1078-0432.22459250
Autor:
Kenneth P. Nephew, John J. Turchi, Daniela Matei, John Lyons, Michael Wagner, Pamela VanderVere-Carozza, Katherine S. Pawelczak, Mohammad Azab, Gavin Choy, Jay Pilrose, David F.B. Miller, Yinu Wang, Pietro Taverna, Jessica Tang, Joanne Munck, Fang Fang
Purpose: To investigate SGI-110 as a “chemosensitizer” in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.Experimental Design: Several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63b056362c489562f254624f63346a0
https://doi.org/10.1158/1078-0432.c.6524180.v1
https://doi.org/10.1158/1078-0432.c.6524180.v1
Autor:
Kenneth P. Nephew, John J. Turchi, Daniela Matei, John Lyons, Michael Wagner, Pamela VanderVere-Carozza, Katherine S. Pawelczak, Mohammad Azab, Gavin Choy, Jay Pilrose, David F.B. Miller, Yinu Wang, Pietro Taverna, Jessica Tang, Joanne Munck, Fang Fang
Supplementary Figure S1. Diagrams of biweekly and QD5 drug (SGI-110 and CDDP) treatment schedules for mice. (A). For non-tumor bearing mice study, mice (3 per group) were injected with different doses of SGI-110 (2 mg/kg, 5 mg/kg, s.c.), CDDP (2 mg/k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::345575d13e7b5d2d0b26a85ea09ca771
https://doi.org/10.1158/1078-0432.22459253
https://doi.org/10.1158/1078-0432.22459253
Autor:
Melissa Khaw, Zachary Davis, Nicholas Zorko, Greg Berk, Gavin Choy, Margaret MacMillan, Martin Felices, Jeffrey S. Miller
Publikováno v:
Cancer Research. 82:3435-3435
Worldwide, Head and Neck Squamous Cell Carcinomas (HNSCC) account for about 900,000 cases and 400,000 deaths. In some settings, like Fanconi anemia (FA), patients receive curative treatments (allogeneic stem cell transplantation), only to develop HNS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2364d8ecc50a9c5c804b335ff9f22e1
https://doi.org/10.1158/1538-7445.am2022-3435
https://doi.org/10.1158/1538-7445.am2022-3435
Autor:
Michael Millward, Gavin Choy, Mark Voskoboynik, Min Gao, Fabio Benedetti, Gary Richardson, Neil Sankar, Xiaoling Zhang, Catriona M. McNeil, Shelly McCurry, Linda Mileshkin, Lisa G. Horvath, Ajit K. Shah
Publikováno v:
Journal of Clinical Oncology. 38:e15125-e15125
e15125 Background: APL-501 is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1). APL-501 is being evaluated in patients (pts) with advanced recurrent and relapsed solid tumors who had not been previously treated with an immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4931c0df6b8e0521cd0cc1531c10f94c
https://doi.org/10.1200/jco.2020.38.15_suppl.e15125
https://doi.org/10.1200/jco.2020.38.15_suppl.e15125
Autor:
Aram Oganesian, Monica M. Mita, Amarpal Sahai, Sanjeev Redkar, Michael S. Gordon, Lee S. Rosen, Pietro Taverna, Nirmal Kapoor, Anthony W. Tolcher, Mohammad Azab, Robert G. Bristow, Gavin Choy
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:195-204
Amuvatinib is an oral multi-kinase inhibitor that suppresses RAD51, inhibits mutant c-KIT and platelet-derived growth factor receptor alpha, and has synergistic activity with DNA-damaging agents and topoisomerase inhibitors such as etoposide, doxorub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5e027fc3a400f01be8a93da67d72fa
https://doi.org/10.1007/s00280-014-2481-1
https://doi.org/10.1007/s00280-014-2481-1
Autor:
Pietro Taverna, Jennifer S. Carew, Steffan T. Nawrocki, Kevin R. Kelly, Francis J. Giles, Gavin Choy, Claudia M. Espitia, Swaminathan Padmanabhan
Publikováno v:
British Journal of Haematology. 156:129-132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f233937a80eb9676afd39b6e7088775
https://doi.org/10.1111/j.1365-2141.2011.08792.x
https://doi.org/10.1111/j.1365-2141.2011.08792.x
Autor:
Mohammad Azab, Sanjeev Redkar, Pietro Taverna, Elizabeth A. Griffiths, Gavin Choy, Adam R. Karpf
Publikováno v:
Drugs of the future. 38(8)
SGI-110 is a second-generation hypomethylating prodrug whose active metabolite is the well-characterized drug decitabine. This novel compound is an oligonucleotide consisting of decitabine linked through a phosphodiester bond to the endogenous nucleo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be68a5f30902c0abc14604f785e8335b
https://pubmed.ncbi.nlm.nih.gov/26190889
https://pubmed.ncbi.nlm.nih.gov/26190889
Autor:
Raoul Tibes, Mohammad Azab, Sanjeev Redkar, Aram Oganesian, Anthony W. Tolcher, Gavin Choy, Amarpal Sahai, Pietro Taverna, Gil Fine
Publikováno v:
Cancer chemotherapy and pharmacology. 71(2)
Amuvatinib is a novel orally administered tyrosine kinase inhibitor with in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51. Amuvatinib was investigated in a first-in-human, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06a6306287257b442567dfcb333002a
https://pubmed.ncbi.nlm.nih.gov/23178951
https://pubmed.ncbi.nlm.nih.gov/23178951